<DOC>
	<DOCNO>NCT02361437</DOCNO>
	<brief_summary>This study design evaluate Vasculera , market medical food product , improve rate extent heal diabetic ulcer .</brief_summary>
	<brief_title>Safety Efficacy VasculeraÂ® Healing Diabetic Skin Ulcers</brief_title>
	<detailed_description>This study design primarily compare rate extent heal diabetic ulcer people treat without Vasculera maintain standard care ( SOC ) therapeutic regimen . The study also examine effect Vasculera anti-diabetic medication requirement marker microvascular disease . Subjects stratify whether receive hyperbaric oxygen therapy ( HBOT ) part SOC treatment regimen . In addition , study examine ability Vasculera improve glycemic control reduce anti-diabetic medication requirement ( oral injectable insulin ) gather preliminary information ability Vasculera improve microvascular blood flow oxygen delivery peripheral tissue include ulcerative lesion .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Skin Ulcer</mesh_term>
	<criteria>1 . Either gender , 2585 year old 2 . Diagnosis type II diabetes 3 . Presence grade IIII skin ulcer diabetic origin least 1 cm diameter 60 day improve despite standard conventional care without HBOT 4 . Treatment oral antidiabetic agent and/or insulin least 1 year . Dose must stable least 3 month . 5 . Not use product control serum glucose include medical food , neutraceuticals dietary supplement 6 . Consistent dietary habit 7 . Able understand sign inform consent document 1. age less 25 year great 85 year 2 . Skin ulceration diabetic etiology 3. diagnosis type I diabetes 4. use serum glucose modify agent , stable prescribe antidiabetic medication regimen within 12 week screen visit 5. use nutritional supplement specifically antioxidative purpose ( e.g. , multivitamin allow ) 6. history collagen vascular disease 7. take corticosteroid dose , route 8. history therapy pentoxyphylline cilostazol 2 month prior screen visit duration study 9. history intestinal disease might interfere absorption study product 10. active malignancy history malignancy within 3 year screen visit , , except basal cell carcinoma cervical carcinoma situ curatively treat 11. screen AST , ALT , alkaline phosphatase , bilirubin &gt; 1.3 time upper limit normal reference laboratory 12. serum creatinine &gt; 3.0 13. diabetes mellitus stable therapy least 3 month 14. history chronic pancreatitis 15. uncontrolled hypertension ( DBP &gt; 100 , SPB &gt; 160 ) 16. unstable angina , uncontrolled cardiac disease include NYHA CHF Class III IV 17. pregnant lactate woman 18. known history allergy citrus , diosmin , Alka4 Complex 19. history substance abuse , psychiatric condition may impair subject 's ability comply study requirement . 20 . Consumption one ( 1 ) unit alcohol daily . For purpose study unit alcohol define 12 oz . beer , 6 oz . wine 1.5 oz . hard spirit 21 . Concomitant use chlorzoxazone , diclofenac metronidazole 22. medical condition , opinion investigator , might put subject undue risk might interfere subject 's ability participate study 23. participation another clinical trial within 30 day 7 halflives prior study product , whichever longer , screen visit</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>diabetes type II</keyword>
	<keyword>diabetic ulcer</keyword>
</DOC>